Merck & CompanyvsUltragenyx Pharmaceutical

MRK and RARE stock compared: price, dividend, valuation and results, from SEC filings.

MRK

Merck & Company, Inc.

$132.81

Value $328B

-3.61%
MRK's page

RARE

Ultragenyx Pharmaceutical Inc.

$17.22

Value $1.8B

-2.88%
RARE's page

Merck & Company (MRK) has a market value of $328B and Ultragenyx Pharmaceutical (RARE) $1.8B. Over the last year, with dividends, MRK moved +41.8% and RARE -47.5%. Dividend yield: MRK 2.56%, RARE none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MRK$328B

    RARE$1.8B

    MRK is 187 times RARE

  • Revenue, 12 months

    MRK$67.4B

    RARE$730M

    MRK is 92 times RARE

  • Net income, 12 months

    MRK$2.5B

    RARE-$524M

  • Operating margin

    MRK–

    RARE-64.0%

  • ROIC

    MRK3.9%

    RARE–

  • P/E

    MRK133.9

    RARE–

  • Dividend yield

    MRK2.6%

    RARE0.0%

    2.6 points apart

  • 5-year return

    MRK+86.3%

    RARE-77.7%

    164.0 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MRK+86.3%

RARE-77.7%

10020020222023202420252026
Returns by period
PeriodMRKWith dividendsRAREWith dividends
1 year since November 18, 2025+41.8%Price +37.7%-47.5%Price -47.5%
3 years since November 17, 2023+43.1%+12.7% a yearPrice +30.5%-56.9%-24.5% a yearPrice -56.9%
5 years since November 18, 2021+86.3%+13.2% a yearPrice +59.9%-77.7%-26.0% a yearPrice -77.7%
10 years since November 21, 2016+203.1%+11.7% a yearPrice +123.4%-79.7%-14.7% a yearPrice -79.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MRKMerck & CompanyRAREUltragenyx Pharmaceutical

Valuation

MRKRARE
Valuation
Price$132.81$17.22
Market value$328B$1.8B
Enterprise value (EV)$372B$1.5B
P/E133.9–
P/E, 5-year median14.8–
P/B7.3–
EV/EBIT78.2–
Free cash flow yield4.5%–

Results and growth

MRKRARE
Results and growth
Revenue, 12 months$67.4B$730M
Net income, 12 months$2.5B-$524M
Free cash flow, 12 months$14.7B-$442M
Earnings per share, 12 months$0.98-$5.18
Revenue growth, year on year1.3%20.2%
Revenue growth a year, past+9.4%over 5 years+20.0%over 5 years
EPS growth a year, past+21.2%over 5 years–

Margins and returns on capital

MRKRARE
Margins and returns on capital
Gross margin71.8%–
Operating margin–-64.0%
Net margin3.6%-71.8%
ROIC3.9%–
ROE5.2%–

Balance sheet

MRKRARE
Balance sheet
Cash$9.7B$266M
Total debt$53.8B$36M
Net debt / EBITDA5.7–
Interest cover2.4×–

Dividends and buybacks

MRKRARE
Dividends and buybacks
Dividend yield2.6%–
Dividend per share, 12 months$3.40–
Dividend growth a year, past+5.8%over 5 years–
Buyback yield1.6%–
Shareholder yield4.1%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MRK or RARE

Didn't find what you were looking for?

Ask us
Which is bigger, Merck & Company or Ultragenyx Pharmaceutical?

By market value, Merck & Company ($328B) is about 187.1 times Ultragenyx Pharmaceutical ($1.8B), at today's prices.

How did MRK and RARE stock do over the last 10 years?

Since November 21, 2016, MRK's price moved +123.4% and RARE's -79.7%. With dividends: MRK +203.1% (+11.7% a year), RARE -79.7% (-14.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, MRK or RARE?

The dividend yield at today's price is 2.56% for Merck & Company and none for Ultragenyx Pharmaceutical. Over the last twelve months they paid $3.40 and – per share.

Which has the higher profit margins, Merck & Company or Ultragenyx Pharmaceutical?

Over the last twelve months, the net margin was 3.6% for Merck & Company and -71.8% for Ultragenyx Pharmaceutical, and the operating margin – and -64.0%. Revenue was $67.4B and $730M.

Which is the better investment, Merck & Company or Ultragenyx Pharmaceutical?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.